Skip to main content
ARYELYON SERAPHOENIX
Close-up portrait of a senior woman representing advanced neuro-therapeutics patient demographics


~145 million people globally face high-risk vision loss from progressive optic neuropathy.​


Engineering the Next-Generation Ocular Neuro-Therapeutics.


Our Deep-Tech Platform pairs Smart Molecules with Nanotechnology for Non-invasive, Sustained Neuroprotection against Progressive Optic Neuropathy.

High-resolution anterior segment photograph of a human eye showing the cornea and iris structure

Overcoming the Limitations of Standard Care.​

Traditional management of optic neuropathies forces a brutal compromise between invasive, high-risk clinical procedures and complex, low-compliance multi-drop regimens.

The Invasiveness Risk: Patients undergo recurring, high-risk surgical or physical interventions, creating massive healthcare system friction.

The Physiological Ceiling: Standard topical interfaces are rapidly cleared by the eye's natural protective mechanisms, severely restricting therapeutic bio-availability.

The Compliance Barrier: Multi-dose tracking creates immense logistical and psychological stress for patients and home caregivers.

Cross-sectional medical illustration highlighting the intravitreal chamber and posterior segment of the eye.

Engineering the Ophthalmic Paradigm Shift.​

A platform engineered to target the multi-pathway root causes of vision degeneration simultaneously.

Sustained Kinetics: Maximizes intraocular residence time, enhancing the therapeutic bioavailability to eliminate high-frequency dosing.

Multi-Pathway Target: Synchronizes a coordinated therapeutic response against oxidative stress, microvascular dysfunction, and localized inflammation.

Active Neuroprotection: Shifts the clinical paradigm from symptom management toward long-term optic nerve protection.

Clinical fundus photograph showing a detailed view of the optic nerve head and retinal blood vessels

The Leadership.​

Dr. Apurva Agrawal


Executive Founder & Designated Partner

B.Tech (Biotechnology) | M.Sc & Ph.D. (Neuroscience) –National Brain Research Centre (NBRC), India

Directs the underlying platform development lifecycle from initial molecular discovery through advanced pre-clinical validation.


Mr. Amod Kumar Agrawal

Co-Founder & Designated Partner

34 Years of Elite Corporate Finance Governance – National Thermal Power Corporation (NTPC) Limited, India

Directs the financial, operational, and corporate governance frameworks required to scale the business.